By Joyce Remi-Babayeju
The Federal Government has received the Long-Acting Injectable Lenacapavir (LEN) for Pre-Exposure Prophylaxis (PrEP) to strengthen HIV prevention efforts in Nigeria. On behalf of the government, the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) under the Federal Ministry of Health and Social Welfare (FMOHSW) confirmed that the medication arrived in Nigeria on March 10, 2026.
In a press statement signed by the Federal Director and National Coordinator of NASCP, Dr. Adebobola Bashorun, the Minister of State for Health and Social Welfare, Iziaq Adekunle Salako, described the development as a major milestone in the country’s HIV prevention efforts.Salako said the approval, with support from the Global Fund, represents a significant advancement in Nigeria’s commitment to expanding innovative HIV prevention options.According to him, the introduction of Lenacapavir for PrEP broadens the range of prevention choices available to individuals at risk of HIV/AIDS infection.“As a long-acting injectable option, LEN PrEP has the potential to improve adherence and expand access to effective HIV prevention services, particularly for populations that face challenges with daily oral prevention methods,” he said.
The minister noted that the arrival of the drug reflects Nigeria’s continued commitment to leveraging innovation and evidence-based interventions to accelerate progress toward epidemic control. He added that by expanding prevention options and strengthening service delivery, Nigeria is taking decisive steps to reduce new HIV infections and improve health outcomes nationwide.NASCP, in collaboration with partners and stakeholders, will ensure the safe introduction, strategic deployment and effective integration of Lenacapavir into the national HIV prevention programme.The rollout, he explained, will support ongoing efforts to expand access to prevention services while reinforcing the country’s broader HIV response.
NASCP reaffirmed its commitment to advancing equitable access to HIV prevention, testing, treatment and care services.
The ministry noted that the arrival of the long-acting injectable Lenacapavir demonstrates Nigeria’s resolve to scale up innovative solutions and strengthen the fight against HIV.“With this development, Nigeria moves closer to ending HIV as a public health threat,” the ministry stated.
